Inhibition of lipid peroxidation in muscle homogenates by phospholipase A2 inhibitors.
Chloropromazine, mepacrine, tetracaine, dibucaine, chloroquine, and procaine have been shown to inhibit the iron- and ascorbate-induced lipid peroxidation of skeletal-muscle homogenates in vitro. These compounds are known to be inhibitors of phospholipase activity, but they were also found to be effective in blocking free-radical-mediated damage to lipids in denatured homogenates, to linoleate suspensions, and to glutamic acid solutions where phospholipase activity was not a relevant factor. The inhibitory action did not appear to be related to any iron-binding activity of the compounds.
D000818:Animals; D002738:Chloroquine / Q000494:pharmacology; D002746:Chlorpromazine / Q000494:pharmacology; D003992:Dibucaine / Q000494:pharmacology; D005260:Female; D005609:Free Radicals; D066298:In Vitro Techniques; D007501:Iron / Q000494:pharmacology; D008054:Lipid Peroxides / Q000096:biosynthesis*; D051379:Mice; D009132:Muscles / Q000187:drug effects* / Q000378:metabolism; D010740:Phospholipases / Q000037:antagonists & inhibitors*; D010741:Phospholipases A / Q000037:antagonists & inhibitors*; D054467:Phospholipases A2; D011343:Procaine / Q000494:pharmacology; D011796:Quinacrine / Q000494:pharmacology; D013748:Tetracaine / Q000494:pharmacology
D005609:Free Radicals; D008054:Lipid Peroxides; D013748:Tetracaine; D011343:Procaine; D002738:Chloroquine; D007501:Iron; D010740:Phospholipases; D010741:Phospholipases A; D054467:Phospholipases A2; D011796:Quinacrine; D003992:Dibucaine; D002746:Chlorpromazine